Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: Results from population-based surveillance

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Cleveland, Angela Ahlquist ^a   Harrison, Lee H ^b   Farley, Monica M ^c   Hollick, Rosemary ^b   Stein, Betsy ^c   Chiller, Tom M ^a   Lockhart, Shawn R ^a   Park, Benjamin J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; EPIDEMIOLOGICAL DATA; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; INCIDENCE; INFANT; INFECTION RISK; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEWBORN; NONHUMAN; POPULATION RESEARCH; PRESCHOOL CHILD; SCHOOL CHILD; UNITED STATES; URBAN AREA; CANDIDA; DRUG EFFECTS; GEORGIA; HEALTH SURVEY; MARYLAND; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

BACTERIA (MICROORGANISMS); CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BALTIMORE; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; GEORGIA; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE; YOUNG ADULT;

EID: 84926512678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120452     Document Type: Article

References (30)

1. US Department of Health and Human Services (USDHHS). National Action Plan to Reduce Health-care-Associated Infections. Washington, DC. 2010. Available at http://www.hhs.gov/ash/initiatives/hai/actionplan/index.html. Accessed December 2, 2013.
2. Lee GM, Kleinman K, Soumerai SB, Tse A, Cole D, Fridkin SK, et al. Effect of nonpayment for preventable infections in U.S. hospitals. N Engl J Med. 2012 Oct 11; 367(15):1428-37. PMID: 23050526. doi: 10.1056/NEJMsa1202419
3. Ong A, Dysert K, Herbert C, Laux L, Granato J, Crawford J, et al. Trends in central line-associated bloodstream infections in a trauma-surgical intensive care unit. Archives of Surgery. 2011; 146(3):302-7. doi: 10.1001/archsurg.2011.9 PMID: 21422361
4. Dixon-Woods M, Perencevich E. Commentary: When Counting Central Line Infections Counts. Infection Control and Hospital Epidemiology. 2013; 34(6):555-7. doi: 10.1086/670630 PMID: 23651884
5. Peasah S, McKay N, Harman J, Al-Amin M, Cook R. Medicare Non-Payment of Hospital-Acquired Infections: Infection Rates Three Years Post Implementation. Medicare & Medicaid Research Review. 2013; 3(3):E1-E15.
6. Jha AK, Joynt KE, Orav EJ, Epstein AM. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med. 2012 Apr 26; 366(17):1606-15. PMID: 22455751. doi: 10.1056/NEJMsa1112351
7. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 Aug 1; 39(3):309-17. PMID: 15306996. Epub 2004/08/13. eng.
8. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: A meta-analysis of costs and financial impact on the us health care system. JAMA Internal Medicine. 2013; 173(22):2039-46. doi: 10.1001/jamainternmed.2013.9763 PMID: 23999949
9. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012 Nov 15; 55(10):1352-61. PMID: 22893576. doi: 10.1093/cid/cis697
10. Schulman J, Stricof R, Stevens TP, Horgan M, Gase K, Holzman IR, et al. Statewide NICU Central-Line-Associated Bloodstream Infection Rates Decline After Bundles and Checklists. Pediatrics. 2008 March 1, 2011; 127(3):436-44. doi: 10.1542/peds.2010-2873 PMID: 21339265
11. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU. New England Journal of Medicine. 2006; 355(26):2725-32. PMID: 17192537
12. Marcos M, Soriano A, Iñurrieta A, Martínez JA, Romero A, Cobos N, et al. Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. Journal of Antimicrobial Chemotherapy. 2011 September 1, 2011; 66(9):2119-25. doi: 10.1093/jac/dkr231 PMID: 21665905
13. Centers for Disease Control and Prevention (CDC). Vital signs: central line-associated blood stream infections - United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep. 2011 Mar 4; 60 (8):243-8. PMID: 21368740. Epub 2011/03/04. eng.
14. Fagan RP, Edwards JR, Park BJ, Fridkin SK, Magill SS. Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990-2010. Infect Control Hosp Epidemiol. 2013 Sep; 34(9):893-9. PMID: 23917902. doi: 10.1086/671724
15. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 2004 Apr; 17 (2):255-67. PMID: 15084500. Pubmed Central PMCID: 387407.
16. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol. 1990 Dec; 28 (12):2733-8. PMID: 2177750. Pubmed Central PMCID: 268264.
17. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol. 2012 Nov; 50(11):3435-42. PMID: 22875889. Pubmed Central PMCID: 3486211. doi: 10.1128/JCM.01283-12
18. Institute CaLS. M27-A3 Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard-third edition. Clinical Laboratory Standards Institute, Wayne, PA2008.
19. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, et al. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013 Dec; 57(12):5836-42. PMID: 24018263. Pubmed Central PMCID: 3837874. doi: 10.1128/AAC.01519-13
20. Pham CD, Bolden CB, Kuykendall RJ, Lockhart SR. Development of a Luminex-Based Multiplex Assay for Detection of Mutations Conferring Resistance to Echinocandins in Candida glabrata. J Clin Microbiol. 2014 Mar; 52(3):790-5. PMID: 24353003. doi: 10.1128/JCM.03378-13
21. Maryland Vital Statistics Annual Report 2012. Division of Health Statistics, Maryland Department of Health and Mental Hygiene, 2012.
22. Estimates of the July 1, 2000-July 1, 2012, United States resident population from the Vintage 2012 postcensal series by year, county, age, sex, race, and Hispanic origin. 2012.
23. Schulman J, Stricof R, Stevens TP, Horgan M, Gase K, Holzman IR, et al. Statewide NICU Central-Line-Associated Bloodstream Infection Rates Decline After Bundles and Checklists. Pediatrics. 2011 March 1, 2011; 127(3):436-44. doi: 10.1542/peds.2010-2873 PMID: 21339265
24. Wise ME, Douglas Scott II R, Baggs JM, Edwards JR, Ellingson KD, Fridkin SK, et al. National Estimates of Central Line-Associated Bloodstream Infections in Critical Care Patients. Infection Control and Hospital Epidemiology. 2013; 34(6):547-54. doi: 10.1086/670629 PMID: 23651883
25. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012 Apr; 50(4):1199-203. PMID: 22278842. Pubmed Central PMCID: 3318516. doi: 10.1128/JCM.06112-11
26. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013 Jun; 56(12):1724-32. PMID: 23487382. Pubmed Central PMCID: 3658363. doi: 10.1093/cid/cit136
27. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 Mar 1; 48(5):503-35. PMID: 19191635. Epub 2009/02/05. eng. doi: 10.1086/596757
28. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013 Aug; 51(8):2571-81. PMID: 23720791. Pubmed Central PMCID: 3719648. doi: 10.1128/JCM.00308-13
29. Lewis JS 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother. 2013 Sep; 57(9):4559-61. PMID: 23817368. Pubmed Central PMCID: 3754289. doi: 10.1128/AAC.01144-13
30. Hammarskjold F, Mernelius S, Andersson RE, Berg S, Hanberger H, Lofgren S, et al. Possible transmission of Candida albicans on an intensive care unit: genotype and temporal cluster analyses. J Hosp Infect. 2013 Sep; 85(1):60-5. PMID: 23927923. doi: 10.1016/j.jhin.2013.06.002